Skip to main content
. 2020 Sep 12;198(5):777–784. doi: 10.1007/s00408-020-00393-8

Fig. 1.

Fig. 1

IL-6 levels at admission and on day 5 of treatment in patients with and without MAS and ARDS p*: 0.001 (Comparison of IL-6 levels at time of admission and day 5 of treatment between groups)